Related Experiment Video

Updated: Apr 21, 2026

Separating Bacteria by Capsule Amount Using a Discontinuous Density Gradient
05:52

Separating Bacteria by Capsule Amount Using a Discontinuous Density Gradient

Published on: January 7, 2019

15.2K

Carbapenemase-producing Klebsiella pneumoniae

Elizabeth Robilotti1, Stan Deresinski1

  • 1Department of Medicine, Division of Infectious Diseases, Stanford University School of Medicine 300 Pasteur Drive, Stanford, CA 94305 USA.

F1000Prime Reports
|October 25, 2014
PubMed

Insights

Multidrug resistant bacteria, like Klebsiella pneumoniae, pose a significant public health threat. Infections caused by carbapenemase-producing K. pneumoniae may paradoxically require carbapenem antibiotics for optimal treatment.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • Emergence of multidrug resistant (MDR) bacteria is a global public health crisis.
  • Klebsiella pneumoniae is a key pathogen, frequently acquiring resistance via mobile genetic elements.
  • Carbapenemase-producing K. pneumoniae strains have spread worldwide.

Purpose of the Study:

  • To highlight the challenge of treating infections caused by MDR Klebsiella pneumoniae.
  • To discuss the complex resistance mechanisms and treatment strategies for carbapenemase-producing K. pneumoniae.

Main Methods:

  • Review of current literature on multidrug resistant Klebsiella pneumoniae.
  • Analysis of resistance mechanisms, including carbapenemase genes (blaKPC, metallo-β-lactamases).
  • Examination of antibiotic resistance profiles beyond beta-lactams (tetracyclines, aminoglycosides, fluoroquinolones).

Main Results:

  • Klebsiella pneumoniae frequently harbors genes for carbapenemases on mobile genetic elements.
  • These strains exhibit resistance to multiple antibiotic classes.
  • Optimal treatment for these infections remains challenging and may paradoxically involve carbapenems.

Conclusions:

  • Carbapenemase-producing Klebsiella pneumoniae represents a critical threat due to extensive antibiotic resistance.
  • Treatment strategies require careful consideration, potentially including carbapenems.
  • Further research is needed to establish definitive optimal therapies.

More Related Videos

Production of Chemicals by Klebsiella pneumoniae Using Bamboo Hydrolysate as Feedstock07:24

Production of Chemicals by Klebsiella pneumoniae Using Bamboo Hydrolysate as Feedstock

Published on: June 29, 2017

8.4K
Author Spotlight: Advancing Rapid Detection of Respiratory Pathogens Using Microfluidic Chip06:11

Author Spotlight: Advancing Rapid Detection of Respiratory Pathogens Using Microfluidic Chip

Published on: March 29, 2024

3.0K

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
73
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
74
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
180
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
17
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.9K
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
74